Synthesis and evaluation of general mechanism-based inhibitors of sulfatases based on (difluoro)methyl phenyl sulfate and cyclic phenyl sulfamate motifs
作者:Sarah R. Hanson、Lisa J. Whalen、Chi-Huey Wong
DOI:10.1016/j.bmc.2006.09.002
日期:2006.12
inhibit sulfatases. The MbI motifs were based on simple aromatic sulfates, which are known to be commonly accepted substrates across this highly conserved enzyme class, so that they might be generally useful for sulfatase labeling studies. (Difluoro)methyl phenol sulfate analogs, constructed to release a reactive quinone methide trap, were not capable of irreversibly inactivating the sulfatase active
A metal‐free method for reduction of cyclic N‐sulfonyl ketimines catalyzed by B(C6F5)3, using commercially available methylphenylsilane as a reducing reagent under mild conditions has been developed. This reductive method was effective, not only providing the expected cyclic N‐Sulfonamides in good to excellent yields, but also showing good functional‐group tolerance.
开发了一种无金属的方法,在温和的条件下,使用市售的甲基苯基硅烷作为还原剂,还原由B(C 6 F 5)3催化的环状N-磺酰基酮亚胺。这种还原方法是有效的,不仅可以提供预期的环状N-磺酰胺类化合物,而且产率很高,而且显示出良好的官能团耐受性。
1-N-phenyl-amino- 1H-imidazole derivatives and pharmaceutical compositions containing them
申请人:LABORATOIRE THERAMEX
公开号:EP1544195A1
公开(公告)日:2005-06-22
The invention relates to the compounds of formula (I):
In which R1, R2, R3, R4, R5, R6, m and n are as defined in the specification, which are potent aromatase and/or steroid sulfatase and/or carbonic anhydrase inhibitors and generally relate to the field of hormone- and non hormone- dependent cancer and endocrine disorders.
The invention also relates to the pharmaceutical compositions containing these compounds.
The invention relates to novel 2,2-dioxo-1,2,3-benzoxathiazines substituted in the benzene nucleus, as well as the 3,4-dihydro analogs thereof, useful as anti-inflammatory, antipyretic, analgesic agents.
1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
申请人:Lafay Jean
公开号:US20070112009A1
公开(公告)日:2007-05-17
The invention relates to the compounds of formula (I):
in which R
1
, R
2
, R
3
, R
4
, Q and Z are as defined in the specification.
The invention also relates to the pharmaceutical compositions containing these compounds.